Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pulmonx Corporation before investing.

In this article, we go over a few key elements for understanding Pulmonx Corporation’s stock price such as:

• Pulmonx Corporation’s current stock price and volume
• Why Pulmonx Corporation’s stock price changed recently
• Upgrades and downgrades for LUNG from analysts
• LUNG’s stock price momentum as measured by its relative strength

About Pulmonx Corporation (LUNG)

Before we jump into Pulmonx Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Want to learn more about Pulmonx Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pulmonx Corporation.

Pulmonx Corporation’s Stock Price as of Market Close

As of April 21, 2026, 10:31 AM, CST, Pulmonx Corporation’s stock price was $1.440.

Pulmonx Corporation is up 1.41% from its previous closing price of $1.420.

During the last market session, Pulmonx Corporation’s stock traded between $1.400 and $1.450. Currently, there are approximately 41.40 million shares outstanding for Pulmonx Corporation.

Pulmonx Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Pulmonx Corporation Stock Price History

Pulmonx Corporation’s (LUNG) price is currently up 11.63% so far this month.

During the month of April, Pulmonx Corporation’s stock price has reached a high of $1.600 and a low of $1.235.

Over the last year, Pulmonx Corporation has hit prices as high as $5.459 and as low as $1.130. Year to date, Pulmonx Corporation’s stock is down 34.84%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pulmonx Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 20, 2026, there was 1 analyst who downgraded Pulmonx Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pulmonx Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pulmonx Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pulmonx Corporation’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pulmonx Corporation (LUNG) by visiting AAII Stock Evaluator.

Relative Price Strength of Pulmonx Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 20, 2026, Pulmonx Corporation has a weighted four-quarter relative price strength of -25.70%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how Pulmonx Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pulmonx Corporation Stock Price: Bottom Line

As of April 21, 2026, Pulmonx Corporation’s stock price is $1.440, which is up 1.41% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pulmonx Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.